We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

PROPPR Trial Supports Use of Transfusion Protocol Initially Developed for Battlefield Trauma Patients

By LabMedica International staff writers
Posted on 04 Mar 2015
Print article
In a groundbreaking multisite prospective clinical trial, the damage control resuscitation (DCR) protocol for massive blood transfusion significantly improved severe trauma patient outcome from hemorrhagic shock, when compared to another commonly used protocol.

DCR, used in most hospitals today, was first developed by a multidisciplinary team of US military trauma surgeons in treating soldiers suffering massive blood loss upon injury in the Afghanistan and Iraq wars. Observational studies suggested that DCR (also called balanced transfusion) improves patient outcomes, then in 2012 researchers launched the large “Pragmatic, Randomized Optimal Platelet and Plasma Ratios” (PROPPR) clinical trial to better gauge its effects. The study involved 680 severely injured patients treated at 12 Level I trauma centers in the US and Canada.

DCR calls for administration of equal parts (1:1:1 ratio) of plasma, platelets, and red blood cells, simultaneously if possible. DCR was tested against a common similar therapy that uses a 1:1:2 ratio of plasma, platelets, and red blood cells. In a head-to-head comparison of randomly assigned patients (within 8 minutes of arriving at a hospital), significantly more patients in the DCR (1:1:1) group achieved hemostasis and fewer experienced death due to exsanguination by 24 hours. Thereafter, mortality rates in the two groups were about the same up to the trial’s 30 day endpoint. The study also addressed concerns of safety by comparing 23 complications and found no significant differences between the two protocols.

“If I needed a massive blood transfusion, I would want DCR,” said Dr. John B. Holcomb, the study’s principal investigator, director of Acute Care Surgery, University of Texas Health Medical School (Houston, TX, USA), and a retired US Army surgeon who had helped develop DCR: “Bleeding to death is the leading, potentially preventable cause of death in military and civilian trauma patients,” he said.

“This is one of the biggest blood transfusion studies ever,” said Dr. Holcomb, “The network involved hundreds of people across North America including doctors, nurses, and technicians. The hard work they put into this study was phenomenal.”

“The National Heart, Lung, and Blood Institute (NHLBI) has a strong commitment to supporting resuscitation research. We were proud to collaborate with the US Department of Defense and our Canadian colleagues in this important trial focused on long-standing clinical questions for treating severe trauma patients,” said Dr. Gail Pearson, director of Adult and Pediatric Cardiac Research, NHLBI, part of the US National Institutes of Health (NIH).

“This study represents a translation of practice from what has been learned during wartime into civilian practice after scientific evaluation. The lessons learned have definitely changed practice and saved lives. Perhaps, as has been said before, this is the only good thing to come out of war,” said Dr. David Hoyt, of the Resuscitation Outcomes Consortium and executive director of the American College of Surgeons.

"This study is an important milestone in trauma care," said Prof. Thomas M. Scalea, MD, Physician-in-Chief of the Cowley Shock Trauma Center, University of Maryland Medical Center (Baltimore, MD, USA), who was part of the committee that designed and oversaw the study. "This impressive collaboration has the potential to yield immediate benefit for trauma patients," said Prof. E. Albert Reece, MD, PhD, MBA, vice president for U. Maryland’s Medical Affairs and dean of the School of Medicine.

The PROPPR Randomized Clinical Trial study, by Holcomb JB et al., was published online February 3, 2015, in the Journal of the American Medical Association (JAMA).

Related Links:

Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR)

Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Liquid Ready-To-Use Lp(a) Reagent
Lipoprotein (a) Reagent

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more


view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.